prochlorperazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2274	58-38-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: prochlorperazine mesylate prochlorperazine capazine chlormeprazine chlorperazine meterazin meterazine proazine prochlorpemazine prochlorperazin prochlorpromazine prochlorperazine maleate prochlorperazine edisylate prochlorperazine dimaleate prochlorperzine	A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612) Molecular weight: 373.94 Formula: C20H24ClN3S CLOGP: 4.58 LIPINSKI: 0 HAC: 3 HDO: 0 TPSA: 9.72 ALOGS: -4.53 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

prochlorperazine mesylate
prochlorperazine
capazine
chlormeprazine
chlorperazine
meterazin
meterazine
proazine
prochlorpemazine
prochlorperazin
prochlorpromazine
prochlorperazine maleate
prochlorperazine edisylate
prochlorperazine dimaleate
prochlorperzine

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Molecular weight: 373.94
Formula: C20H24ClN3S
CLOGP: 4.58
LIPINSKI: 0
HAC: 3
HDO: 0
TPSA: 9.72
ALOGS: -4.53
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O
50	mg	P
0.10	g	R

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.83 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	15 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	22 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	16 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	9 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Oct. 23, 1956	FDA	GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	346.01	11.57	467	52489	97200	50454968
Drug ineffective	301.57	11.57	251	52705	819082	49733086
Disease progression	257.20	11.57	402	52554	95464	50456704
Dehydration	236.43	11.57	504	52452	151945	50400223
Diarrhoea	216.94	11.57	1196	51760	587280	49964888
Plasma cell myeloma	216.86	11.57	212	52744	31110	50521058
Nausea	213.56	11.57	1361	51595	704037	49848131
White blood cell count decreased	206.99	11.57	408	52548	116314	50435854
Vomiting	197.47	11.57	977	51979	459781	50092387
Platelet count decreased	147.95	11.57	326	52630	100400	50451768
Contraindicated product administered	141.25	11.57	3	52953	148955	50403213
Fatigue	140.09	11.57	1236	51720	706365	49845803
Death	125.72	11.57	671	52285	324708	50227460
Neutropenia	122.86	11.57	387	52569	147578	50404590
Synovitis	115.47	11.57	3	52953	123862	50428306
Systemic lupus erythematosus	113.19	11.57	9	52947	140613	50411555
Arthropathy	109.79	11.57	17	52939	157889	50394279
Constipation	108.78	11.57	433	52523	185275	50366893
Malignant neoplasm progression	99.41	11.57	220	52736	67904	50484264
Asthenia	95.93	11.57	616	52340	318426	50233742
Toxicity to various agents	95.08	11.57	52	52904	212447	50339721
Therapeutic product effect decreased	93.77	11.57	15	52941	136035	50416133
Joint swelling	90.96	11.57	74	52882	245212	50306956
Decreased appetite	81.98	11.57	421	52535	200502	50351666
Glossodynia	79.05	11.57	13	52943	115556	50436612
Blood magnesium decreased	76.20	11.57	75	52881	11085	50541083
Neutrophil count decreased	75.61	11.57	156	52800	45870	50506298
Abdominal pain	72.06	11.57	458	52498	235770	50316398
Full blood count decreased	71.68	11.57	102	52854	22244	50529924
Neovascularisation	71.35	11.57	30	52926	983	50551185
Neoplasm progression	69.50	11.57	116	52840	29041	50523127
Neuropathy peripheral	69.43	11.57	241	52715	96516	50455652
Hospice care	66.01	11.57	52	52904	5720	50546448
Thrombosis	65.88	11.57	166	52790	55667	50496501
Pericarditis	63.39	11.57	5	52951	78684	50473484
Pleural effusion	62.94	11.57	208	52748	81246	50470922
Heart rate abnormal	61.45	11.57	43	52913	3949	50548219
Therapeutic product effect incomplete	61.03	11.57	11	52945	91504	50460664
Condition aggravated	60.26	11.57	139	52817	296919	50255249
Akathisia	59.36	11.57	57	52899	8172	50543996
Carbohydrate antigen 125 increased	58.83	11.57	35	52921	2432	50549736
Rheumatoid arthritis	56.15	11.57	78	52878	202472	50349696
Lymphadenitis	53.88	11.57	34	52922	2626	50549542
Clostridium difficile infection	53.80	11.57	96	52860	25343	50526825
Gangrene	53.07	11.57	42	52914	4650	50547518
Completed suicide	51.10	11.57	38	52918	131851	50420317
Small intestinal obstruction	51.02	11.57	73	52883	15995	50536173
Arterial occlusive disease	50.06	11.57	41	52915	4767	50547401
Infusion related reaction	49.32	11.57	63	52893	169494	50382674
Thrombocytopenia	48.21	11.57	262	52694	127411	50424757
Red blood cell count decreased	47.90	11.57	108	52848	33727	50518441
Drug abuse	47.66	11.57	4	52952	59842	50492326
Drug intolerance	47.30	11.57	99	52857	219005	50333163
Swelling	46.60	11.57	87	52869	200785	50351383
Cytokine release syndrome	46.32	11.57	51	52905	8583	50543585
Maternal exposure during pregnancy	45.82	11.57	60	52896	159718	50392450
Injection site pain	45.63	11.57	30	52926	110994	50441174
Colitis	44.86	11.57	114	52842	38415	50513753
Pancytopenia	44.42	11.57	190	52766	83840	50468328
Lower respiratory tract infection	42.96	11.57	23	52933	95178	50456990
Wound	42.92	11.57	29	52927	105765	50446403
Coma	42.17	11.57	5	52951	56874	50495294
Hepatic enzyme increased	42.11	11.57	49	52907	137331	50414837
Injection site erythema	42.10	11.57	13	52943	74923	50477245
Pain	41.44	11.57	397	52559	578506	49973662
Pneumonitis	39.35	11.57	92	52864	29418	50522750
Palmar-plantar erythrodysaesthesia syndrome	38.90	11.57	73	52883	20025	50532143
Weight decreased	38.54	11.57	377	52579	220868	50331300
Failure to thrive	38.41	11.57	40	52916	6318	50545850
General physical health deterioration	38.31	11.57	56	52900	142378	50409790
Pneumonia	37.28	11.57	579	52377	377822	50174346
Treatment failure	36.16	11.57	55	52901	137582	50414586
Paradoxical drug reaction	35.68	11.57	30	52926	3617	50548551
Intentional overdose	34.83	11.57	11	52945	62493	50489675
Hair colour changes	34.33	11.57	26	52930	2698	50549470
Alopecia areata	34.17	11.57	20	52936	1348	50550820
Blood creatine increased	33.65	11.57	33	52923	4854	50547314
Hair texture abnormal	33.57	11.57	29	52927	3627	50548541
Injection site reaction	33.38	11.57	6	52950	50026	50502142
Haemoglobin decreased	32.35	11.57	236	52720	126980	50425188
Mobility decreased	32.31	11.57	22	52934	79926	50472242
Anaemia	31.98	11.57	404	52552	252052	50300116
Discomfort	31.78	11.57	40	52916	108340	50443828
Hypokalaemia	31.48	11.57	178	52778	87814	50464354
Blood potassium decreased	30.92	11.57	97	52859	36848	50515320
Rectal cancer metastatic	30.39	11.57	11	52945	239	50551929
Off label use	30.33	11.57	334	52622	474092	50078076
Hyponatraemia	30.22	11.57	188	52768	95951	50456217
Folliculitis	30.21	11.57	3	52953	39222	50512946
Back pain	29.97	11.57	357	52599	219673	50332495
Mucosal inflammation	29.65	11.57	101	52855	40041	50512127
Suicide attempt	29.01	11.57	9	52947	51723	50500445
Irritable bowel syndrome	28.75	11.57	9	52947	51432	50500736
Taste disorder	28.18	11.57	39	52917	8285	50543883
Hypophagia	28.17	11.57	78	52878	27650	50524518
Sepsis	27.95	11.57	236	52720	132689	50419479
Musculoskeletal stiffness	27.74	11.57	58	52898	128423	50423745
Drug hypersensitivity	26.97	11.57	390	52566	250620	50301548
Knee arthroplasty	26.94	11.57	3	52953	35843	50516325
Psoriatic arthropathy	26.70	11.57	8	52948	47024	50505144
Muscle twitching	26.15	11.57	53	52903	15378	50536790
Oral pain	26.01	11.57	71	52885	24962	50527206
Injection site swelling	25.81	11.57	6	52950	41767	50510401
Dysgeusia	25.38	11.57	94	52862	38822	50513346
Exposure during pregnancy	24.99	11.57	56	52900	120959	50431209
Weight increased	24.62	11.57	118	52838	201773	50350395
Red cell distribution width increased	24.45	11.57	37	52919	8522	50543646
Overdose	24.17	11.57	42	52914	99685	50452483
Pyrexia	23.31	11.57	541	52415	379662	50172506
Drug interaction	23.01	11.57	119	52837	199502	50352666
Deep vein thrombosis	22.81	11.57	143	52813	73161	50479007
Skin exfoliation	22.60	11.57	82	52874	33530	50518638
Gastric disorder	22.39	11.57	75	52881	29473	50522695
Arthralgia	22.35	11.57	324	52632	438378	50113790
Laboratory test abnormal	22.32	11.57	64	52892	23144	50529024
Hypersensitivity	22.22	11.57	133	52823	215028	50337140
Ill-defined disorder	22.13	11.57	15	52941	54639	50497529
Lymphadenopathy	21.92	11.57	81	52875	33418	50518750
Cholestasis of pregnancy	21.77	11.57	14	52942	1117	50551051
Hip arthroplasty	21.76	11.57	3	52953	30426	50521742
C-reactive protein increased	21.13	11.57	23	52933	66451	50485717
Red blood cell sedimentation rate increased	20.81	11.57	3	52953	29413	50522755
Autoimmune nephritis	20.74	11.57	9	52947	319	50551849
Hypoxia	20.70	11.57	107	52849	51016	50501152
Extrapyramidal disorder	20.63	11.57	41	52915	11729	50540439
Abdominal discomfort	20.49	11.57	150	52806	231491	50320677
Fibromyalgia	20.09	11.57	11	52945	44967	50507201
Dry skin	20.05	11.57	94	52862	43097	50509071
Pulmonary embolism	19.51	11.57	177	52779	101527	50450641
Tumour marker increased	19.43	11.57	22	52934	3818	50548350
Loss of personal independence in daily activities	19.36	11.57	27	52929	70023	50482145
Skull fracture	19.17	11.57	12	52944	914	50551254
Nasopharyngitis	19.01	11.57	121	52835	192806	50359362
Madarosis	18.97	11.57	18	52938	2542	50549626
Plasma cell myeloma recurrent	18.40	11.57	18	52938	2640	50549528
Breast cancer metastatic	18.04	11.57	36	52920	10328	50541840
Injection site bruising	17.92	11.57	8	52948	36760	50515408
Injection site pruritus	17.88	11.57	10	52946	40401	50511767
Product use issue	17.85	11.57	88	52868	149387	50402781
Mental status changes	17.62	11.57	80	52876	36192	50515976
Abortion spontaneous	17.55	11.57	11	52945	41761	50510407
Acquired cystic kidney disease	17.47	11.57	5	52951	49	50552119
Intentional product misuse	17.41	11.57	14	52942	46720	50505448
Anuria	17.16	11.57	37	52919	11207	50540961
Coronary artery disease	16.97	11.57	5	52951	29721	50522447
Lymphocyte count decreased	16.70	11.57	63	52893	26244	50525924
Morbid thoughts	16.45	11.57	9	52947	533	50551635
Streptococcal bacteraemia	16.38	11.57	13	52943	1445	50550723
Impaired healing	16.36	11.57	30	52926	69756	50482412
Clostridium difficile colitis	16.17	11.57	48	52908	17694	50534474
Psoriasis	15.87	11.57	30	52926	68970	50483198
Multiple sclerosis relapse	15.84	11.57	13	52943	42951	50509217
Drug reaction with eosinophilia and systemic symptoms	15.83	11.57	5	52951	28419	50523749
Parkinsonism	15.73	11.57	31	52925	8816	50543352
Blood pressure fluctuation	15.65	11.57	9	52947	35814	50516354
Enteritis	15.57	11.57	27	52929	6968	50545200
Therapeutic response decreased	15.39	11.57	16	52940	47215	50504953
Pancreatic carcinoma recurrent	15.35	11.57	5	52951	78	50552090
Pregnancy	15.11	11.57	6	52950	29571	50522597
Chills	15	11.57	161	52795	96526	50455642
Oesophagitis	14.95	11.57	39	52917	13344	50538824
Intentional self-injury	14.93	11.57	3	52953	23109	50529059
Ovarian cancer recurrent	14.75	11.57	10	52946	872	50551296
Haematocrit decreased	14.71	11.57	74	52882	34902	50517266
Hypermagnesaemia	14.63	11.57	10	52946	884	50551284
Dyssomnia	14.48	11.57	4	52952	34	50552134
Dyspepsia	14.23	11.57	129	52827	73968	50478200
Asthma	14.19	11.57	47	52909	89290	50462878
Bacteraemia	14.07	11.57	40	52916	14393	50537775
Acute myeloid leukaemia	13.94	11.57	41	52915	15033	50537135
Ascites	13.79	11.57	74	52882	35787	50516381
Hypomagnesaemia	13.51	11.57	54	52902	23102	50529066
Heart rate decreased	13.51	11.57	11	52945	36486	50515682
Diabetes mellitus	13.45	11.57	19	52937	49014	50503154
Lymph node pain	13.39	11.57	11	52945	1284	50550884
Cataract	13.32	11.57	90	52866	47210	50504958
Systemic inflammatory response syndrome	13.26	11.57	21	52935	5028	50547140
Embolism	13.10	11.57	25	52931	6943	50545225
Inflammation	12.87	11.57	25	52931	56887	50495281
Alopecia	12.78	11.57	180	52776	244867	50307301
Dizziness	12.66	11.57	462	52494	345907	50206261
Plasmacytoma	12.64	11.57	14	52942	2371	50549797
Dysphagia	12.45	11.57	130	52826	77388	50474780
Palpitations	12.25	11.57	152	52804	94354	50457814
Urinary tract infection	12.25	11.57	314	52642	223706	50328462
Enterocolitis infectious	12.13	11.57	11	52945	1467	50550701
Wrong technique in product usage process	12.02	11.57	25	52931	55485	50496683
Stomatitis	11.88	11.57	160	52796	101184	50450984
Non-small cell lung cancer	11.85	11.57	15	52941	2922	50549246
Gastrointestinal injury	11.74	11.57	7	52949	488	50551680
Osteoporosis	11.71	11.57	18	52938	44861	50507307
Neutropenic sepsis	11.70	11.57	37	52919	14110	50538058
Sedation	11.61	11.57	9	52947	30601	50521567
Lethargy	11.59	11.57	90	52866	49342	50502826

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	355.41	12.47	535	33626	111705	29428661
Fatigue	194.44	12.47	800	33361	316021	29224345
Plasma cell myeloma	184.77	12.47	221	33940	36894	29503472
Disease progression	135.66	12.47	295	33866	81621	29458745
Nausea	134.81	12.47	674	33487	288581	29251785
Dehydration	128.02	12.47	355	33806	114393	29425973
Death	101.51	12.47	708	33453	341376	29198990
Malignant neoplasm progression	98.09	12.47	244	33917	73615	29466751
Diarrhoea	95.99	12.47	684	33477	332014	29208352
Pneumonia	91.60	12.47	657	33504	319515	29220851
Vomiting	90.50	12.47	483	33678	211777	29328589
Decreased appetite	84.59	12.47	362	33799	144980	29395386
Drug abuse	72.81	12.47	5	34156	79878	29460488
Drug interaction	69.95	12.47	75	34086	197310	29343056
White blood cell count decreased	68.58	12.47	232	33929	83130	29457236
Drug ineffective	64.14	12.47	211	33950	362959	29177407
Toxicity to various agents	63.75	12.47	64	34097	173597	29366769
Neuropathy peripheral	58.69	12.47	198	33963	70829	29469537
Full blood count decreased	57.26	12.47	81	34080	15911	29524455
Constipation	55.64	12.47	270	33891	113890	29426476
Condition aggravated	54.73	12.47	53	34108	146242	29394124
Platelet count decreased	50.59	12.47	247	33914	104425	29435941
Completed suicide	48.12	12.47	22	34139	90224	29450142
Meconium abnormal	43.94	12.47	11	34150	54	29540312
Neutropenia	43.80	12.47	281	33880	131430	29408936
Neutrophil count decreased	40.98	12.47	127	34034	43440	29496926
Overdose	40.20	12.47	21	34140	79798	29460568
Hospice care	38.95	12.47	38	34123	5030	29535336
Rash	38.06	12.47	360	33801	189459	29350907
Neoplasm progression	37.78	12.47	73	34088	18539	29521827
Failure to thrive	36.95	12.47	45	34116	7639	29532727
Small intestinal obstruction	36.58	12.47	59	34102	13002	29527364
Cytokine release syndrome	35.03	12.47	58	34103	13061	29527305
Back pain	32.61	12.47	216	33945	102068	29438298
Necrotising enterocolitis neonatal	31.15	12.47	11	34150	200	29540166
Deep vein thrombosis	31.02	12.47	140	34021	57259	29483107
Product use in unapproved indication	30.71	12.47	33	34128	86842	29453524
Asthenia	30.51	12.47	381	33780	214869	29325497
Therapeutic product effect incomplete	29.39	12.47	5	34156	39300	29501066
Intentional overdose	28.60	12.47	5	34156	38523	29501843
Muscle spasms	28.19	12.47	149	34012	64933	29475433
Sepsis	27.76	12.47	269	33892	142413	29397953
Coma	25.48	12.47	7	34154	39443	29500923
Bradycardia	25.42	12.47	23	34138	65606	29474760
Adverse drug reaction	25.40	12.47	73	34088	23947	29516419
Rhabdomyolysis	25.15	12.47	20	34141	60788	29479578
Intentional product misuse	24.65	12.47	5	34156	34656	29505710
Suicide attempt	24.10	12.47	5	34156	34105	29506261
Off label use	24.04	12.47	227	33934	300573	29239793
Thrombosis	24.01	12.47	106	34055	42939	29497427
Pulmonary embolism	24	12.47	161	34000	76373	29463993
General physical health deterioration	23.91	12.47	52	34109	102805	29437561
Ageusia	23.17	12.47	39	34122	8899	29531467
Injection site pain	22.42	12.47	5	34156	32441	29507925
Cardiac failure	21.09	12.47	37	34124	79250	29461116
Laboratory test abnormal	20.93	12.47	57	34104	18128	29522238
Hiccups	20.82	12.47	37	34124	8816	29531550
Oral pain	20.74	12.47	38	34123	9269	29531097
Spinal cord compression	20.60	12.47	23	34138	3559	29536807
Dysgeusia	20.30	12.47	65	34096	22609	29517757
Psoriasis	20.29	12.47	6	34155	32221	29508145
Coronary artery disease	20.28	12.47	13	34148	44177	29496189
Hyponatraemia	19.85	12.47	140	34021	67493	29472873
Bacteraemia	19.62	12.47	52	34109	16271	29524095
Wrong technique in product usage process	19.52	12.47	6	34155	31422	29508944
Fluid imbalance	19.11	12.47	8	34153	234	29540132
C-reactive protein increased	19.01	12.47	14	34147	44249	29496117
Rheumatoid arthritis	18.47	12.47	7	34154	32145	29508221
Weight decreased	18.38	12.47	260	33901	150645	29389721
Treatment failure	18.18	12.47	10	34151	36929	29503437
Pleural effusion	17.26	12.47	142	34019	71766	29468600
Hypophagia	17.04	12.47	58	34103	20814	29519552
Drug reaction with eosinophilia and systemic symptoms	16.24	12.47	6	34155	27986	29512380
Diaphragmatic rupture	16.08	12.47	4	34157	19	29540347
Clostridium difficile infection	16.05	12.47	48	34113	16093	29524273
Dystonia	15.96	12.47	35	34126	9714	29530652
Bacillus bacteraemia	15.85	12.47	5	34156	63	29540303
Mental status changes	15.83	12.47	81	34080	34846	29505520
Inappropriate schedule of product administration	15.59	12.47	17	34144	44455	29495911
Plasma cell myeloma recurrent	15.21	12.47	20	34141	3663	29536703
Anaemia	14.98	12.47	320	33841	200631	29339735
Mixed dementia	14.92	12.47	7	34154	270	29540096
Laparotomy	14.85	12.47	7	34154	273	29540093
Inferior vena caval occlusion	14.77	12.47	4	34157	28	29540338
Immune effector cell-associated neurotoxicity syndrome	14.76	12.47	13	34148	1511	29538855
Oesophagitis	14.35	12.47	38	34123	11885	29528481
Haematochezia	14.27	12.47	13	34148	36970	29503396
Temperature intolerance	13.87	12.47	17	34144	2904	29537462
Peripheral swelling	13.79	12.47	123	34038	63616	29476750
Cholestasis	13.66	12.47	5	34156	23457	29516909
Red blood cell count decreased	13.49	12.47	62	34099	25540	29514826
Abdominal distension	13.44	12.47	95	34066	45816	29494550
Pancytopenia	13.40	12.47	151	34010	83017	29457349
Pneumonitis	13.38	12.47	66	34095	27978	29512388
Hypoxia	13.27	12.47	97	34064	47282	29493084
Wrist deformity	13.25	12.47	7	34154	349	29540017
Cholangiocarcinoma	13.20	12.47	10	34151	940	29539426
Therapeutic response decreased	13.19	12.47	6	34155	24705	29515661
Seizure	13.17	12.47	59	34102	93064	29447302
Tooth disorder	13.16	12.47	32	34129	9497	29530869
Blood potassium decreased	13.09	12.47	44	34117	15690	29524676
Therapeutic product effect decreased	13.06	12.47	9	34152	29442	29510924
Drug dependence	13.04	12.47	4	34157	20977	29519389
Oral candidiasis	12.73	12.47	34	34127	10688	29529678
Myocardial infarction	12.70	12.47	75	34086	110221	29430145
Respiratory arrest	12.70	12.47	7	34154	25826	29514540
Enterocolitis infectious	12.49	12.47	11	34150	1278	29539088

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	739.58	11.25	958	68449	186699	64242626
Disease progression	322.24	11.25	560	68847	141120	64288205
Dehydration	316.34	11.25	711	68696	216052	64213273
Plasma cell myeloma	279.32	11.25	294	69113	45781	64383544
Nausea	250.30	11.25	1569	67838	784231	63645094
Drug ineffective	230.03	11.25	344	69063	839903	63589422
Vomiting	229.48	11.25	1183	68224	549934	63879391
Fatigue	227.14	11.25	1477	67930	747253	63682072
Diarrhoea	225.53	11.25	1436	67971	721268	63708057
White blood cell count decreased	213.75	11.25	503	68904	157334	64271991
Platelet count decreased	147.69	11.25	456	68951	167255	64262070
Toxicity to various agents	142.19	11.25	110	69297	363403	64065922
Malignant neoplasm progression	141.20	11.25	349	69058	112522	64316803
Death	120.22	11.25	909	68498	481796	63947529
Pneumonia	116.25	11.25	1011	68396	558565	63870760
Decreased appetite	114.55	11.25	601	68806	280688	64148637
Neutropenia	112.42	11.25	533	68874	239091	64190234
Constipation	111.90	11.25	516	68891	228821	64200504
Drug abuse	108.72	11.25	9	69398	132365	64296960
Neoplasm progression	102.31	11.25	169	69238	40795	64388530
Contraindicated product administered	102.16	11.25	3	69404	107826	64321499
Neutrophil count decreased	100.01	11.25	242	69165	76954	64352371
Completed suicide	99.58	11.25	59	69348	224355	64204970
Synovitis	93.00	11.25	3	69404	99087	64330238
Asthenia	91.67	11.25	779	68628	427265	64002060
Small intestinal obstruction	84.25	11.25	115	69292	23458	64405867
Condition aggravated	81.97	11.25	174	69233	372252	64057073
Cytokine release syndrome	78.07	11.25	104	69303	20725	64408600
Failure to thrive	76.98	11.25	74	69333	10330	64418995
Arthropathy	76.65	11.25	18	69389	120949	64308376
Blood magnesium decreased	75.92	11.25	84	69323	13821	64415504
Therapeutic product effect decreased	75.43	11.25	16	69391	115335	64313990
Full blood count decreased	74.48	11.25	106	69301	22476	64406849
Therapeutic product effect incomplete	72.69	11.25	12	69395	103470	64325855
Abdominal pain	71.86	11.25	578	68829	311797	64117528
Hospice care	71.61	11.25	62	69345	7563	64421762
Sepsis	70.77	11.25	457	68950	229884	64199441
Thrombosis	70.57	11.25	201	69206	70441	64358884
Drug interaction	68.65	11.25	183	69224	361900	64067425
Pleural effusion	68.61	11.25	294	69113	126265	64303060
Neovascularisation	68.09	11.25	30	69377	1073	64428252
Joint swelling	66.84	11.25	80	69327	215302	64214023
Off label use	66.07	11.25	405	69002	632401	63796924
Clostridium difficile infection	64.57	11.25	129	69278	36034	64393291
Coma	64.19	11.25	9	69398	87606	64341719
Neuropathy peripheral	58.38	11.25	266	69141	117259	64312066
Systemic lupus erythematosus	56.79	11.25	8	69399	77604	64351721
Intentional overdose	55.77	11.25	14	69393	89930	64339395
Injection site pain	55.76	11.25	25	69382	111383	64317942
Heart rate abnormal	53.58	11.25	44	69363	4991	64424334
General physical health deterioration	53.34	11.25	86	69321	204339	64224986
Overdose	53.06	11.25	56	69351	159510	64269815
Hyponatraemia	49.05	11.25	300	69107	148039	64281286
Pancytopenia	48.77	11.25	292	69115	143017	64286308
Carbohydrate antigen 125 increased	46.95	11.25	28	69379	1900	64427425
Thrombocytopenia	45.50	11.25	403	69004	223398	64205927
Hair colour changes	44.84	11.25	35	69372	3692	64425633
Colitis	44.73	11.25	152	69255	58522	64370803
Pneumonitis	44.29	11.25	137	69270	50228	64379097
Akathisia	43.95	11.25	58	69349	11452	64417873
Drug intolerance	43.70	11.25	85	69322	187907	64241418
Palmar-plantar erythrodysaesthesia syndrome	42.39	11.25	95	69312	28724	64400601
Lymphadenitis	42.23	11.25	34	69373	3751	64425574
Suicide attempt	42.23	11.25	12	69395	70995	64358330
Pulmonary embolism	41.65	11.25	285	69122	146071	64283254
Deep vein thrombosis	41.50	11.25	223	69184	104959	64324366
Back pain	41.24	11.25	431	68976	249740	64179585
Red blood cell count decreased	41.06	11.25	130	69277	48256	64381069
Hypophagia	39.87	11.25	113	69294	39474	64389851
Rheumatoid arthritis	39.30	11.25	73	69334	164221	64265104
Gangrene	37.78	11.25	43	69364	7295	64422030
Oral pain	37.54	11.25	88	69319	27405	64401920
Anaemia	37.22	11.25	593	68814	378087	64051238
Weight decreased	36.25	11.25	468	68939	285271	64144054
Arterial occlusive disease	35.85	11.25	41	69366	6992	64422333
Dysgeusia	35.09	11.25	121	69286	46926	64382399
Intentional product misuse	34.97	11.25	17	69390	72278	64357047
C-reactive protein increased	34.21	11.25	31	69376	94878	64334447
Pyrexia	33.91	11.25	813	68594	557831	63871494
Mental status changes	33.05	11.25	142	69265	61020	64368305
Lower respiratory tract infection	32.81	11.25	32	69375	94582	64334743
Nasopharyngitis	32.80	11.25	105	69302	195968	64233357
Coronary artery disease	32.77	11.25	12	69395	60421	64368904
Bacteraemia	32.33	11.25	82	69325	26829	64402496
Injection site erythema	32.24	11.25	18	69389	70782	64358543
Hypoxia	32.17	11.25	183	69224	87966	64341359
Alopecia areata	31.62	11.25	20	69387	1508	64427817
Injection site reaction	31.48	11.25	6	69401	46658	64382667
Pericarditis	31.32	11.25	14	69393	62502	64366823
Haemoglobin decreased	31.15	11.25	334	69073	194729	64234596
Drug reaction with eosinophilia and systemic symptoms	30.72	11.25	10	69397	54207	64375118
Mucosal inflammation	30.57	11.25	141	69266	62443	64366882
Oesophagitis	30.37	11.25	70	69337	21560	64407765
Rectal cancer metastatic	30.29	11.25	13	69394	436	64428889
Blood potassium decreased	30.21	11.25	104	69303	40295	64389030
Hair texture abnormal	29.38	11.25	25	69382	2979	64426346
Musculoskeletal stiffness	27.51	11.25	57	69350	123149	64306176
Hepatic enzyme increased	27.45	11.25	62	69345	129881	64299444
Rhabdomyolysis	27.45	11.25	35	69372	91691	64337634
Dry skin	27.04	11.25	118	69289	51043	64378282
Bradycardia	26.98	11.25	54	69353	118165	64311160
Blood pressure fluctuation	26.97	11.25	11	69396	51860	64377465
Injection site swelling	26.49	11.25	6	69401	41347	64387978
Psoriatic arthropathy	26.32	11.25	7	69400	43274	64386051
Immune effector cell-associated neurotoxicity syndrome	26.21	11.25	22	69385	2573	64426752
Enterocolitis infectious	25.11	11.25	21	69386	2443	64426882
Glossodynia	24.69	11.25	20	69387	64676	64364649
Cardiac failure	23.47	11.25	69	69338	132304	64297021
Eosinophilia	23.46	11.25	6	69401	38070	64391255
Red blood cell sedimentation rate increased	23.37	11.25	3	69404	31232	64398093
Red cell distribution width increased	23.29	11.25	45	69362	12264	64417061
Weight increased	22.96	11.25	135	69272	213213	64216112
Hypokalaemia	22.95	11.25	216	69191	121687	64307638
Swelling	22.67	11.25	92	69315	160126	64269199
Non-small cell lung cancer	22.42	11.25	27	69380	4863	64424462
Folliculitis	22.24	11.25	3	69404	30074	64399251
Paradoxical drug reaction	22.08	11.25	30	69377	6090	64423235
Discomfort	22.05	11.25	33	69374	80845	64348480
Performance status decreased	21.99	11.25	28	69379	5336	64423989
Hepatitis	21.62	11.25	11	69396	45571	64383754
Mobility decreased	21.54	11.25	37	69370	85803	64343522
Cholestasis of pregnancy	21.40	11.25	13	69394	912	64428413
Systemic inflammatory response syndrome	21.33	11.25	39	69368	10196	64419129
Hypersensitivity	21.31	11.25	124	69283	196328	64232997
Infusion related reaction	21.10	11.25	98	69309	164369	64264956
Heart rate decreased	21.04	11.25	17	69390	55050	64374275
Taste disorder	21.01	11.25	37	69370	9396	64419929
Muscle twitching	20.88	11.25	56	69351	18942	64410383
Ageusia	20.84	11.25	46	69361	13767	64415558
Cytomegalovirus infection	20.83	11.25	7	69400	37192	64392133
Treatment failure	20.63	11.25	61	69346	116755	64312570
Pain	20.48	11.25	447	68960	553064	63876261
Asthma	20.46	11.25	45	69362	95180	64334145
Enteritis	20.27	11.25	42	69365	12035	64417290
Wound	20.09	11.25	32	69375	76445	64352880
Madarosis	19.99	11.25	18	69389	2312	64427013
Psoriasis	19.80	11.25	29	69378	71674	64357651
Sedation	19.67	11.25	10	69397	41452	64387873
Medication error	19.63	11.25	15	69392	49951	64379374
Blood creatine increased	19.38	11.25	33	69374	8159	64421166
Hypermagnesaemia	19.37	11.25	13	69394	1084	64428241
Streptococcal bacteraemia	19.34	11.25	20	69387	3047	64426278
Blood pressure systolic increased	19.23	11.25	15	69392	49438	64379887
Wrong technique in product usage process	19.22	11.25	25	69382	64949	64364376
Intentional self-injury	19.04	11.25	4	69403	29040	64400285
Metastatic renal cell carcinoma	18.91	11.25	17	69390	2179	64427146
Hypophosphataemia	18.89	11.25	46	69361	14674	64414651
Product use in unapproved indication	18.87	11.25	112	69295	176506	64252819
Embolism	18.75	11.25	41	69366	12194	64417131
Loss of personal independence in daily activities	18.39	11.25	31	69376	72423	64356902
Klebsiella bacteraemia	17.99	11.25	17	69390	2323	64427002
Lymphocyte count decreased	17.92	11.25	89	69318	40610	64388715
Depressed level of consciousness	17.90	11.25	38	69369	81398	64347927
Haematocrit decreased	17.70	11.25	110	69297	54545	64374780
Therapeutic response decreased	17.69	11.25	18	69389	52170	64377155
Dysphagia	17.55	11.25	184	69223	106628	64322697
Inflammation	17.46	11.25	27	69380	65273	64364052
Stomatitis	17.17	11.25	187	69220	109418	64319907
Cancer pain	17.10	11.25	22	69385	4235	64425090
Cholestasis	16.96	11.25	14	69393	44858	64384467
Injection site bruising	16.92	11.25	9	69398	36364	64392961
Injection site pruritus	16.67	11.25	10	69397	37816	64391509
Acquired cystic kidney disease	16.65	11.25	5	69402	57	64429268
Dizziness	16.40	11.25	591	68816	429572	63999753
Ill-defined disorder	16.34	11.25	14	69393	44038	64385287
Cholangitis	16.32	11.25	36	69371	10766	64418559
Autoimmune nephritis	16.13	11.25	9	69398	538	64428787
Clostridium difficile colitis	16.11	11.25	65	69342	27158	64402167
Arthralgia	16.09	11.25	358	69049	441902	63987423
Osteoporosis	16.07	11.25	13	69394	42067	64387258
Hypoglycaemia	15.83	11.25	47	69360	89845	64339480
Retching	15.80	11.25	44	69363	15212	64414113
Product use issue	15.79	11.25	97	69310	151618	64277707
Exposure during pregnancy	15.65	11.25	38	69369	77637	64351688
Impaired healing	15.23	11.25	26	69381	60447	64368878
Fluid imbalance	15.19	11.25	8	69399	426	64428899
Mixed dementia	15.09	11.25	7	69400	283	64429042
Drug hypersensitivity	14.94	11.25	348	69059	237467	64191858
Spinal cord compression	14.87	11.25	24	69383	5679	64423646
Anaphylactic shock	14.86	11.25	7	69400	30321	64399004
Lymph node pain	14.78	11.25	12	69395	1340	64427985
Diabetes mellitus	14.62	11.25	31	69376	66443	64362882
Dystonia	14.48	11.25	49	69358	18816	64410509
Inferior vena caval occlusion	14.48	11.25	4	69403	33	64429292
Therapeutic drug monitoring analysis incorrectly performed	14.42	11.25	6	69401	186	64429139
Gastric disorder	14.42	11.25	66	69341	29131	64400194
Stress	14.37	11.25	27	69380	60507	64368818
Tumour marker increased	14.13	11.25	18	69389	3432	64425893
Respiratory arrest	14.08	11.25	22	69385	52963	64376362
Hyperglycaemia	14.06	11.25	113	69294	60855	64368470
Feeding disorder	14.06	11.25	38	69369	12911	64416414
Diabetes mellitus inadequate control	13.84	11.25	3	69404	21318	64408007
Pancreatic carcinoma recurrent	13.70	11.25	5	69402	108	64429217
Cardiogenic shock	13.70	11.25	9	69398	32418	64396907
Inappropriate schedule of product administration	13.68	11.25	52	69355	92234	64337091
Renal cell carcinoma	13.67	11.25	24	69383	6080	64423245
Arthritis infective	13.67	11.25	26	69381	7004	64422321
Hypoalbuminaemia	13.65	11.25	46	69361	17628	64411697
Bacillus bacteraemia	13.53	11.25	5	69402	112	64429213
Skull fracture	13.41	11.25	12	69395	1529	64427796
Oral candidiasis	13.40	11.25	55	69352	23157	64406168
Myocardial infarction	13.39	11.25	114	69293	165707	64263618
Mean cell haemoglobin concentration decreased	13.20	11.25	18	69389	3666	64425659
Agranulocytosis	13.17	11.25	13	69394	38216	64391109
Muscle spasms	13.12	11.25	219	69188	140804	64288521
Abdominal infection	13.10	11.25	16	69391	2924	64426401
Drug dependence	13.09	11.25	10	69397	33302	64396023
Multiple sclerosis relapse	13.04	11.25	15	69392	41120	64388205
Colon cancer metastatic	12.96	11.25	13	69394	1910	64427415
Atrial fibrillation	12.87	11.25	257	69150	170832	64258493
Pancreatic carcinoma	12.87	11.25	32	69375	10341	64418984
Fear	12.77	11.25	3	69404	20168	64409157
Acute myeloid leukaemia	12.77	11.25	61	69346	27402	64401923
Hiccups	12.75	11.25	28	69379	8348	64420977
Lymphadenopathy	12.72	11.25	90	69317	46596	64382729
Therapy non-responder	12.68	11.25	33	69374	65866	64363459
Irritable bowel syndrome	12.54	11.25	13	69394	37356	64391969
Skin exfoliation	12.51	11.25	87	69320	44798	64384527
Urinary tract infection	12.49	11.25	332	69075	231264	64198061
Metastases to liver	12.48	11.25	55	69352	23886	64405439
Pancreatic carcinoma metastatic	12.47	11.25	17	69390	3461	64425864
Aggression	12.47	11.25	19	69388	46213	64383112
Cholangiocarcinoma	12.44	11.25	13	69394	2005	64427320
Maternal exposure during pregnancy	12.37	11.25	57	69350	95827	64333498
Lung squamous cell carcinoma metastatic	12.32	11.25	4	69403	60	64429265
Haematochezia	12.20	11.25	34	69373	66339	64362986
Oesophageal ulcer	12.11	11.25	23	69384	6187	64423138
Obstructive airways disorder	11.92	11.25	5	69402	23180	64406145
Liver injury	11.74	11.25	9	69398	29923	64399402
Hypovolaemia	11.69	11.25	40	69367	15446	64413879
Hypogeusia	11.66	11.25	11	69396	1500	64427825
Injury	11.59	11.25	27	69380	55965	64373360
Lymphatic disorder	11.56	11.25	6	69401	310	64429015
Spasmodic dysphonia	11.48	11.25	5	69402	174	64429151
Oxygen saturation decreased	11.42	11.25	68	69339	107108	64322217
Morbid thoughts	11.39	11.25	8	69399	718	64428607
Fibromyalgia	11.36	11.25	13	69394	35718	64393607
Drug level increased	11.36	11.25	12	69395	34184	64395141
Pneumothorax	11.32	11.25	54	69353	24244	64405081
Chills	11.28	11.25	209	69198	137055	64292270
Blood sodium decreased	11.27	11.25	62	69345	29420	64399905

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05AB04	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Phenothiazines with piperazine structure
FDA CS	M0016525	Phenothiazines
MeSH PA	D000932	Antiemetics
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
CHEBI has role	CHEBI:37890	alpha-adrenergic receptor blockaders
CHEBI has role	CHEBI:48561	dopaminergic antagonists
CHEBI has role	CHEBI:48873	acetylcholine receptor antagonist
CHEBI has role	CHEBI:50919	antiemetico
CHEBI has role	CHEBI:65190	typical antipsychotic drugs
CHEBI has role	CHEBI:76779	post-proline endopeptidase inhibitors
CHEBI has role	CHEBI:131787	D2R antagonist
FDA EPC	N0000175746	Phenothiazine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Nausea and vomiting	indication	16932000
Schizophrenia	indication	58214004	DOID:5419
Nonpsychotic Anxiety	indication
Prolonged-Severe Nausea and Vomiting	indication
Migraine	off-label use	37796009	DOID:6364
Chemotherapy-induced nausea and vomiting	off-label use	236084000
Brain damage	contraindication	2470005
Tachyarrhythmia	contraindication	6285003
Urinary tract obstruction	contraindication	7163005	DOID:5200
Alcoholism	contraindication	7200002
Organophosphate poisoning	contraindication	8260003
Weight gain finding	contraindication	8943002
Severe chronic ulcerative colitis	contraindication	14311001
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Chronic disease of respiratory system	contraindication	17097001
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Toxic megacolon	contraindication	28536002	DOID:1770
Orthostatic hypotension	contraindication	28651003
Atony of colon	contraindication	29479008
Torsades de pointes	contraindication	31722008
Parkinsonism	contraindication	32798002
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Complete trisomy 21 syndrome	contraindication	41040004	DOID:14250
Conduction disorder of the heart	contraindication	44808001
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Paralytic ileus	contraindication	55525008	DOID:8442
Peptic reflux disease	contraindication	57643001
Ulcerative colitis	contraindication	64766004	DOID:8577
Drug AND/OR toxin-induced diarrhea	contraindication	65979008
Extrapyramidal disease	contraindication	76349003
Spastic paralysis	contraindication	78403003
Disturbance of salivary secretion	contraindication	78948009
Hyperglycemia	contraindication	80394007	DOID:4195
Hiatal hernia	contraindication	84089009	DOID:12642
Epilepsy	contraindication	84757009	DOID:1826
Leukopenia	contraindication	84828003	DOID:615
Stupor	contraindication	89458003
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Tardive dyskinesia	contraindication	102449007
Prolonged QT interval	contraindication	111975006
Gastrointestinal obstruction	contraindication	126765001
Acute disease of cardiovascular system	contraindication	128487001
Autonomic dysreflexia	contraindication	129618003
Bleeding	contraindication	131148009
Angina pectoris	contraindication	194828000
Myocardial dysfunction	contraindication	233928007
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Metabolic syndrome X	contraindication	237602007	DOID:14221
Hyperprolactinemia	contraindication	237662005	DOID:12700
Pyloric obstruction	contraindication	244815007
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Anemia	contraindication	271737000	DOID:2355
Drowsy	contraindication	271782001
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Coma	contraindication	371632003
At risk for aspiration	contraindication	371736008
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Visual impairment	contraindication	397540003
Gastric ulcer	contraindication	397825006	DOID:10808
Breastfeeding (mother)	contraindication	413712001
Chronic lung disease	contraindication	413839001
Disorder of coronary artery	contraindication	414024009
Myocardial ischemia	contraindication	414795007	DOID:3393
Obesity	contraindication	414916001	DOID:9970
Congenital long QT syndrome	contraindication	442917000
Carcinoma of female breast	contraindication	447782002

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Gastrointestinal disturbances associated with emotional stress	Indication
Dogs	Gastrointestinal disturbances associated with emotional stress	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Darbazine Spansule Capsule No.1	Zoetis Inc.	2
Darbazine Injectable	Zoetis Inc.	2
Neo-Darbazine Spansule Capsule No.1, Neo-Darbazine Spansule Capsule No.3	Zoetis Inc.	3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.74	Basic
pKa2	4.74	Basic
pKa3	2.21	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	8.76	WOMBAT-PK	CHEMBL
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	ANTAGONIST	Ki	8.61	WOMBAT-PK	IUPHAR
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	7.20	DRUG MATRIX
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.64	DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		Ki	5.82	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	6.21	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	6.40	DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.23	PDSP
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	7.82	WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.19	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.91	WOMBAT-PK
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.91	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	7.62	WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	8.32	DRUG MATRIX
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	7.72	WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	6.61	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	5.96	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	6.49	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	6.72	DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	6.80	DRUG MATRIX
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.92	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.86	DRUG MATRIX
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	6.52	DRUG MATRIX
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	7.17	WOMBAT-PK
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.89	DRUG MATRIX
Cytochrome P450 1A2	Enzyme	P05177	CP1A2_HUMAN		IC50	5.70	DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.25	DRUG MATRIX
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.30	CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	7.11	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.31	DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	5.92	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	6.38	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	7.49	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	6.02	CHEMBL
5-hydroxytryptamine receptor 4	GPCR		5HT4R_CAVPO		Ki	6.71	DRUG MATRIX
Pleiotropic ABC efflux transporter of multiple drugs	Transporter		PDR5_YEAST		IC50	5.77	CHEMBL

External reference:

ID	Source
4018001	VUID
N0000146346	NUI
D00479	KEGG_DRUG
84-02-6	SECONDARY_CAS_RN
1257-78-9	SECONDARY_CAS_RN
4017999	VANDF
4018000	VANDF
4018001	VANDF
C0033229	UMLSCUI
CHEBI:8435	CHEBI
P77	PDB_CHEM_ID
CHEMBL728	ChEMBL_ID
DB00433	DRUGBANK_ID
CHEMBL1200587	ChEMBL_ID
CHEMBL1314751	ChEMBL_ID
CHEMBL1201154	ChEMBL_ID
D011346	MESH_DESCRIPTOR_UI
4917	PUBCHEM_CID
7279	IUPHAR_LIGAND_ID
699	INN_ID
YHP6YLT61T	UNII
235739	RXNORM
2073	MMSL
5361	MMSL
5362	MMSL
5363	MMSL
6416	MMSL
6417	MMSL
d00355	MMSL
001478	NDDF
001479	NDDF
001480	NDDF
003466	NDDF
22827004	SNOMEDCT_US
372853006	SNOMEDCT_US
3823007	SNOMEDCT_US
395843006	SNOMEDCT_US
79129001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5105	TABLET, FILM COATED	5 mg	ORAL	ANDA	14 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5110	TABLET, FILM COATED	10 mg	ORAL	ANDA	14 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	0440-8190	TABLET	5 mg	ORAL	ANDA	12 sections
Compro	HUMAN PRESCRIPTION DRUG LABEL	1	0574-7226	SUPPOSITORY	25 mg	RECTAL	ANDA	19 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6135	INJECTION	5 mg	INTRAMUSCULAR	ANDA	18 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6135	INJECTION	5 mg	INTRAMUSCULAR	ANDA	18 sections
Prochlorperazine	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0135	SUPPOSITORY	25 mg	RECTAL	ANDA	13 sections
Prochlorperazine	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0135	SUPPOSITORY	25 mg	RECTAL	ANDA	13 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0351	INJECTION	5 mg	INTRAMUSCULAR	ANDA	13 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0351	INJECTION	5 mg	INTRAMUSCULAR	ANDA	13 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5020	TABLET, FILM COATED	5 mg	ORAL	ANDA	18 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5021	TABLET, FILM COATED	10 mg	ORAL	ANDA	18 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	10544-281	TABLET	10 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	10544-511	TABLET	5 mg	ORAL	ANDA	12 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	14789-700	INJECTION	5 mg	INTRAMUSCULAR	ANDA	18 sections
PROCHLORPERAZINE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-327	TABLET	10 mg	ORAL	ANDA	10 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-571	TABLET	5 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-572	TABLET	10 mg	ORAL	ANDA	12 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-294	INJECTION	5 mg	INTRAMUSCULAR	ANDA	13 sections
PROCHLORPERAZINE EDISYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-497	INJECTION	5 mg	INTRAMUSCULAR	ANDA	12 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-523	INJECTION	5 mg	INTRAMUSCULAR	ANDA	13 sections
PROCHLORPERAZINE EDISYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	25021-790	INJECTION	5 mg	INTRAVENOUS	ANDA	18 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	33261-141	TABLET	5 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	33261-550	TABLET	10 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	42291-728	TABLET	5 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	42291-729	TABLET	10 mg	ORAL	ANDA	12 sections
Prochlorperazine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	42708-103	TABLET	10 mg	ORAL	ANDA	12 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	43063-353	TABLET, FILM COATED	5 mg	ORAL	ANDA	14 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	43063-742	TABLET	10 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	43063-742	TABLET	10 mg	ORAL	ANDA	12 sections